Data / Drug companies / Excella GmbH & Co. KG
Excella GmbH & Co. KG: 74 products in the FDA NDC directory, labeler code 46014
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Excella GmbH & Co. KG (labeler code 46014) lists 74 products in the FDA National Drug Code Directory. By type: 52 bulk ingredients, 22 prescription drugs. Its main marketing category is bulk ingredients. The newest product started marketing on June 16, 2026.
The request: Watch Excella GmbH & Co. KG (FDA labeler code 46014): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 46014
- Products in commercial distribution
- 74
- Packages
- 75
- Finished drugs by generic name
- 0
- Prescription products
- 22
- Over the counter products
- 0
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- June 30, 1988
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 42 | 56.8% |
| Drugs for further processing | 22 | 29.7% |
| Bulk ingredients for compounding | 10 | 13.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 52 | 70.3% |
| Prescription drugs | 22 | 29.7% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 49 | 66.2% |
| Capsule | 13 | 17.6% |
| Tablet, film coated | 6 | 8.1% |
| Tablet | 2 | 2.7% |
| Injection, solution | 2 | 2.7% |
| Kit | 1 | 1.4% |
| Injection | 1 | 1.4% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Methotrexate disodium | 46014-1500 | Powder | Bulk ingredients | June 16, 2026 |
| Timolol maleate | 46014-1490 | Powder | Bulk ingredients | June 9, 2026 |
| Timolol(s)base hemihydrate | 46014-1159 | Powder | Bulk ingredients | December 12, 2025 |
| Paroxetine | 46014-9076 | Capsule | Drugs for further processing | February 18, 2025 |
| Tryvio | 46014-8012 | Capsule | Drugs for further processing | October 1, 2024 |
| Anastrozole | 46014-1161 | Powder | Bulk ingredients | July 18, 2024 |
| Buspirone hydrochloride sieved | 46014-1480 | Powder | Bulk ingredients | April 18, 2024 |
| Temozolomide | 46014-1460 | Powder | Bulk ingredients | January 1, 2024 |
| Thioguanine | 46014-6302 | Tablet | Drugs for further processing | May 15, 2023 |
| Busulfan | 46014-6202 | Tablet, film coated | Drugs for further processing | May 15, 2023 |
| Chlorambucil | 46014-6102 | Tablet, film coated | Drugs for further processing | May 15, 2023 |
| Ropivacaine hydrochloride | 46014-1470 | Injection, solution | Bulk ingredients | March 1, 2023 |
| Pirenzepine monohydrate | 46014-1210 | Powder | Bulk ingredients | April 1, 2022 |
| Tamoxifen citrate | 46014-1200 | Powder | Bulk ingredients | January 3, 2022 |
| Tamoxifen citrate | 46014-1190 | Powder | Bulk ingredients | January 3, 2022 |
| Tamoxifen citrate | 46014-1180 | Powder | Bulk ingredients | January 3, 2022 |
| Anastrozole | 46014-1160 | Powder | Bulk ingredients | May 12, 2021 |
| Relugolix | 46014-1130 | Powder | Bulk ingredients for compounding | December 18, 2020 |
| Azacitidine | 46014-7300 | Tablet, film coated | Drugs for further processing | September 1, 2020 |
| Azacitidine | 46014-7200 | Tablet, film coated | Drugs for further processing | September 1, 2020 |
| Firocoxib | 46014-1112 | Powder | Bulk ingredients | May 12, 2020 |
| Deracoxib milled | 46014-1170 | Powder | Bulk ingredients | February 5, 2020 |
| Talazoparib | 46014-1140 | Powder | Bulk ingredients | October 1, 2018 |
| Temozolomide | 46014-1450 | Powder | Bulk ingredients | March 1, 2018 |
| Methotrexate | 46014-1133 | Powder | Bulk ingredients | November 29, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.